Key Findings
A growing base of geriatric population triggering the incidence rates of target disorders will be attributed to the market growth in North America. The market is expected to propel at a CAGR of 9.73% during the forecasted years 2019-2027.

Market Insights
The United States neurostimulation device market is mainly driven owing to the increasing geriatric population which includes escalating cases of Alzheimer’s and Parkinson’s disease along with investments made by the government institutions in research & development activities for Alzheimer’s diseases. The US was the largest revenue contributor to this region in 2018 because of the increased use of neurostimulation devices for various diseases. Advances in technology and the availability of reimbursement by Medicare propel market growth in the country will be responsible for the market development in future.

Competitive Insights
Major market players in the region are Cogentix Medical Inc., St. Jude Medical Inc. (acquired by Abbott Laboratories), Aleva Neurotherapeutics SA, Boston Scientific Corporation, Helius Medical Technologies, The Magstim Company Limited, Cyberonics Inc., Neuronetics Inc., Depuy Synthes Companies, Ekso Bionics Holding Inc., Medtronic PLC, Dr. Langer Medical GmBH, Ectron Limited, Nevro Corp. and Hocoma AG.